{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:52:33Z","timestamp":1787313153072,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000008","name":"Health Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000008","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017560","name":"Saskatchewan Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008920","name":"University of Saskatchewan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016628","name":"University of Saskatchewan College of Pharmacy and Nutrition","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.neuint.2025.106039","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T15:51:38Z","timestamp":1756223498000},"page":"106039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["In vitro pharmacological activity of twenty-eight synthetic cannabinoid receptor agonists at the type 1 and 2 cannabinoid receptors"],"prefix":"10.1016","volume":"190","author":[{"given":"Gabrielle","family":"Mercier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawthar A.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayat","family":"Zagzoog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cropper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Laprairie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuint.2025.106039_bib1","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/jms.1558","article-title":"\u2018Spice\u2019 and other herbal belnds: harmless incense or cannabinoid designer drugs?","volume":"44","author":"Auw\u00e4rter","year":"2009","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.neuint.2025.106039_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/164_2018_144","article-title":"The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: evolution","volume":"252","author":"Banister","year":"2018","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuint.2025.106039_bib3","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1021\/acschemneuro.5b00107","article-title":"Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135","volume":"6","author":"Banister","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuint.2025.106039_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1098\/rspb.1983.0093","article-title":"Operational models of pharmacological agonism","volume":"220","author":"Black","year":"1983","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.neuint.2025.106039_bib5","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1111\/j.1476-5381.2011.01503.x","article-title":"AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor","volume":"165","author":"Bolognini","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuint.2025.106039_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.919605","article-title":"Pharmacological evaluation of enantiomerically separated positive allosteric modulators of cannabinoid 1 receptor, GAT591 and GAT593","volume":"13","author":"Brandt","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuint.2025.106039_bib7","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1021\/acschemneuro.0c00644","volume":"11","author":"Cannaert","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuint.2025.106039_bib8","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/dta.3285","article-title":"A new cannabinoid receptor 1 selective agonist evading the 2021 \u201cChina ban\u201d: ADB\u2010FUBIATA","volume":"14","author":"Deventer","year":"2022","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neuint.2025.106039_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lfs.2013.09.017","article-title":"Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to \u0394(9)-THC: mechanism underlying greater toxicity?","volume":"97","author":"Fantegrossi","year":"2014","journal-title":"Life Sci."},{"key":"10.1016\/j.neuint.2025.106039_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.901","article-title":"Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: analogues of the synthetic cannabinoid receptor agonist EG-018","volume":"10","author":"Finlay","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.neuint.2025.106039_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1021\/jm901214q","article-title":"Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity","volume":"53","author":"Frost","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuint.2025.106039_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaz3140","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists","volume":"13","author":"Gillis","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.neuint.2025.106039_bib13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1360-0443.2012.04078.x","article-title":"Acute toxicity due to the confrmed consumption of synthetic cannabinoids: clinical and laboratory findings","volume":"108","author":"Hermanns-Clausen","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.neuint.2025.106039_bib14","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1111\/febs.16741","article-title":"Synthetic cannabinoid receptor agonists are monoamine oxidase-A selective inhibitors","volume":"290","author":"Hindson","year":"2023","journal-title":"FEBS J."},{"key":"10.1016\/j.neuint.2025.106039_bib15","article-title":"Narrative review of the pharmacodynamics, pharmacokinetics, and toxicities of illicit synthetic cannabinoid receptor agonists","author":"Houston","year":"2023","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.neuint.2025.106039_bib16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/bs.apha.2017.03.007","article-title":"CB1 and CB2 receptor pharmacology","volume":"80","author":"Howlett","year":"2017","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuint.2025.106039_bib17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2020.01.008","article-title":"Activation and signaling mechanism revealed by cannabinoid Receptor-Gi complex structures","volume":"180","author":"Hua","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.neuint.2025.106039_bib18","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2174\/0929867054020864","article-title":"Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes","volume":"12","author":"Huffman","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuint.2025.106039_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bmc.2004.09.050","article-title":"Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists","volume":"13","author":"Huffman","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuint.2025.106039_bib20","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1016\/j.bmcl.2006.07.051","article-title":"1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors","volume":"16","author":"Huffman","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.neuint.2025.106039_bib21","doi-asserted-by":"crossref","first-page":"13581","DOI":"10.1021\/jacs.3c00129","article-title":"Axially chiral cannabinoids: design, synthesis, and cannabinoid receptor affinity","volume":"145","author":"Kearney","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.neuint.2025.106039_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.1048836","article-title":"Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11","volume":"13","author":"Kevin","year":"2022","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuint.2025.106039_bib23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41467-018-08162-1","article-title":"Phosphorylation-deficient G-protein-biased \u03bc-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects","volume":"21","author":"Kliewer","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuint.2025.106039_bib24","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1111\/bph.15811","article-title":"Community guidelines for GPCR ligand bias: IUPHAR review 32","volume":"179","author":"Kolb","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuint.2025.106039_bib25","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.cell.2018.11.040","article-title":"Structure of a signaling cannabinoid receptor 1-G protein complex","volume":"176","author":"Krishna Kumar","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.neuint.2025.106039_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.forsciint.2015.12.046","article-title":"Synthetic cannabinoid drug use as a cause or contributory cause of death","volume":"260","author":"Labay","year":"2016","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.neuint.2025.106039_bib27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/mol.115.101980","article-title":"Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease","volume":"89","author":"Laprairie","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuint.2025.106039_bib28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cell.2018.12.011","article-title":"Crystal structure of the human cannabinoid receptor CB2","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.neuint.2025.106039_bib29","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1016\/j.cell.2023.11.017","article-title":"Snapshot of the cannabinoid receptor 1-arrestin complex unravels the biased signaling mechanism","volume":"186","author":"Liao","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.neuint.2025.106039_bib30","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1124\/pharmrev.122.000600","article-title":"Good and bads of the endocannabinoid system as a therapeutic target: lessons learned after 30 years","volume":"75","author":"Maccarrone","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuint.2025.106039_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115686","article-title":"Unveiling the angiogenic effects of cannabinoids: enhancers or inhibitors?","volume":"215","author":"Maia","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuint.2025.106039_bib32","author":"Makriyannis","year":"2000","journal-title":"Cannabimimetic indole derivatives"},{"key":"10.1016\/j.neuint.2025.106039_bib33","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1007\/s00213-022-06191-9","article-title":"Adolescent self-administration of the synthetic cannabinoid receptor agonist JWH-018 induces neurobiological and behavioral alterations in adult male mice","volume":"239","author":"Margiani","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuint.2025.106039_bib34","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1021\/acschemneuro.2c00034","article-title":"Defining steric requirements at CB1 and CB2 cannabinoid receptors using synthetic cannabinoid receptor agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and their analogues","volume":"13","author":"Markham","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuint.2025.106039_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173467","article-title":"In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists","volume":"220","author":"Marusich","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuint.2025.106039_bib36","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fnmol.2018.00487","article-title":"Cannabinoid ligands targeting TRP channels","volume":"11","author":"Muller","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuint.2025.106039_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1157","article-title":"Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB2 receptor","volume":"11","author":"Patel","year":"2023","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.neuint.2025.106039_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106961","article-title":"IUPHAR themed review: opioid efficacy, bias, and selectivity","volume":"197","author":"Ramos-Gonzalez","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuint.2025.106039_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116052","article-title":"Investigating selectivity and bias for G protein subtypes and \u03b2-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB1 receptor","volume":"222","author":"Ryalls","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuint.2025.106039_bib40","doi-asserted-by":"crossref","first-page":"590","DOI":"10.4062\/biomolther.2015.120","article-title":"Assessment of the abuse liability of synthetic cannabinoid agonists JWH-030, JWH-175, and JWH-176","volume":"23","author":"Tampus","year":"2015","journal-title":"Biomol Ther (Seoul)"},{"key":"10.1016\/j.neuint.2025.106039_bib41","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41467-024-55808-4","article-title":"Structural basis of THC analog activity at the Cannabinoid 1 receptor","volume":"16","author":"Thorsen","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuint.2025.106039_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108795","article-title":"Cannabinoid receptor 1 ligands: biased signaling mechanisms driving functionally selective drug discovery","volume":"267","author":"Tian","year":"2025","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuint.2025.106039_bib43","doi-asserted-by":"crossref","first-page":"8030","DOI":"10.3390\/ijms23148030","article-title":"In vivo bio-activation of JWH-175 to JWH-018: pharmacodynamic and pharmacokinetic studies in mice","volume":"23","author":"Tirri","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuint.2025.106039_bib44","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1248\/cpb.59.1203","article-title":"Identification of a novel cannabimimetic phenylacetylindole, cannabipiperidiethanone, as a designer drug in a herbal product and its affinity for cannabinoid CB1 and CB2 receptors","volume":"59","author":"Uchiyama","year":"2011","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.neuint.2025.106039_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.08.025","article-title":"Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists","volume":"169","author":"Wouters","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuint.2025.106039_bib46","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1021\/acschemneuro.3c00530","article-title":"Subtle structural modification of a synthetic cannabinoid receptor agonist drastically increases its efficacy at the CB1 receptor","volume":"14","author":"Yano","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuint.2025.106039_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90167-w","article-title":"Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor","volume":"11","author":"Zagzoog","year":"2021","journal-title":"Sci. Rep."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018625001123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018625001123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:46:00Z","timestamp":1780407960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018625001123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":47,"alternative-id":["S0197018625001123"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2025.106039","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro pharmacological activity of twenty-eight synthetic cannabinoid receptor agonists at the type 1 and 2 cannabinoid receptors","name":"articletitle","label":"Article Title"},{"value":"Neurochemistry International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuint.2025.106039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106039"}}